WEIGUANG BIOLOGICAL(SZ:002880) Shang Hai Zheng Quan Bao·2025-04-22 19:59Core Viewpoint - The company, Shenzhen Weiguang Biological Products Co., Ltd., is engaged in the research, production, and sales of blood products, which are crucial for medical emergencies and are considered strategic reserves by the state. The company has proposed a cash dividend distribution plan based on its financial performance in 2024. Company Overview - The company specializes in blood products, including albumin, immunoglobulin, and coagulation factors, which are derived from healthy human blood or plasma. These products play an irreplaceable role in medical emergencies, wars, and major disasters [3][4]. Industry Development - The blood products industry in China has seen significant growth since its introduction in the 1960s, with fewer than 30 companies currently operating. Major international players hold over 80% of the global market share [4][5]. - The industry has high entry barriers and strict regulatory oversight, with no new production companies approved since 2001. The government has implemented comprehensive regulations covering all aspects of blood product production [5][6]. Market Potential - The global blood products market is expected to grow due to increasing patient numbers and the rising usage rates of immunoglobulin and albumin. In China, the per capita demand for blood products is anticipated to increase significantly, with a large space for domestic production to replace imports [6][7]. - In 2024, China's plasma collection is projected to reach approximately 13,400 tons, indicating substantial growth potential compared to developed countries [6][7]. Future Industry Trends - Domestic demand for blood products is expected to rise, driven by an aging population and increased medical needs. The number of plasma collection stations is likely to increase, enhancing supply capabilities [6][7]. - Companies are focusing on technological research and development to improve the utilization rate of plasma and expand product offerings [7][8]. Company Position - The company is one of the earliest blood product manufacturers in China and has a strong operational management capability with nine plasma collection stations. It ranks among the top in plasma collection volume within the industry [10][11]. - The company has established a cooperative agreement with Belarus for the production and technology transfer of blood products, marking it as the first in China to achieve technology export in this field [11]. Financial Data - In 2024, the company reported a net profit of approximately 253.52 million yuan, with a proposed cash dividend of 2 yuan per 10 shares, totaling 45.36 million yuan [60][62].